SCHEMBL1450339

SCHEMBL1450339

OCCn1ccc2cc[c]cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 4/20 0.41
CCND1 P24385 4/20 0.41
LMNA P02545 1/20 0.36
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
MAPK1 P28482 2/20 0.33
KMO O15229 1/20 0.33
KMT2A Q03164 2/20 0.32
MCL1 Q07820 1/20 0.32
TSHR P16473 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C19 P33261 1/20 0.31
PLG P00747 1/20 0.31
PLAU P00749 1/20 0.31
ACACB O00763 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1450476 0.86 CDK4 (0.41) CDK4CCND1LMNAHTR2AHTR2C
SCHEMBL6183003 0.82 CDK4 (0.41) CDK4CCND1LMNAHTR2AHTR2C
SCHEMBL5042221 0.79 CDK4 (0.44) CDK4CCND1LMNAHTR2AHTR2C
SCHEMBL13726782 0.78 CDK4 (0.38) CDK4CCND1HTR2AHTR2CMAPK1
SCHEMBL1451115 0.78 HTR2C (0.61) CDK4CCND1HTR2AHTR2C
SCHEMBL2365253 0.78 CDK4 (0.35) CDK4CCND1HTR2AHTR2CKMT2A
SCHEMBL6401477 0.77 KMT2A (0.39) CDK4CCND1HTR2AHTR2CKMT2A
SCHEMBL29275177 0.77 MAPK1 (0.37) CDK4CCND1MAPK1KMT2ASMN1; SMN2
SCHEMBL16719844 0.76 CDK4 (0.44) CDK4CCND1LMNAHTR2AHTR2C
SCHEMBL5778193 0.76 CDK4 (0.41) CDK4CCND1HTR2AHTR2CMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3068758-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE The Wistar Institute Of Anatomy And Biology (US) 2016-09-21 EP disclosed
WO-2015073864-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2015-05-21 WO disclosed
US-8383839-B2 Heterocyclidene acetamide derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2013-02-26 US disclosed
US-20110112071-A1 NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2011-05-12 US disclosed
US-7910751-B2 Heterocyclidene acetamide derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2011-03-22 US disclosed
US-20080287428-A1 Novel Heterocyclidene Acetamide Derivative MOCHIDA PHARMACEUTICAL CO.,LTD (JP) 2008-11-20 US disclosed
EP-1908753-A1 NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287428-A1 Novel Heterocyclidene Acetamide Derivative TRPV1, TRPV3, TRPA1 CDK4 635/4885CCND1 307/4885LMNA 3355/4885
US-20110112071-A1 NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE TRPV1, TRPV3, TRPA1 CDK4 635/4885CCND1 307/4885LMNA 3355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.